iktos
Iktos is a company leveraging cutting-edge AI and robotics to transform drug discovery. Their integrated platform covers the entire DMTA cycle, from generative AI-driven molecular design with Makya, to AI-driven retrosynthesis planning with Spaya, and automated synthesis and testing via Iktos Robotics. This approach aims to significantly shorten the drug discovery phase, targeting under 2 years for candidate development. Iktos collaborates with pharmaceutical, biotech, and academic institutions, showcasing over 60 partnerships. They also develop their own pipeline of drug candidates. The company was founded in 2016 and has secured significant funding, including a €15.5M Series A round in 2023, and acquired Synsight in July 2024 to enhance their biology platform.
iktos
Iktos is a company leveraging cutting-edge AI and robotics to transform drug discovery. Their integrated platform covers the entire DMTA cycle, from generative AI-driven molecular design with Makya, to AI-driven retrosynthesis planning with Spaya, and automated synthesis and testing via Iktos Robotics. This approach aims to significantly shorten the drug discovery phase, targeting under 2 years for candidate development. Iktos collaborates with pharmaceutical, biotech, and academic institutions, showcasing over 60 partnerships. They also develop their own pipeline of drug candidates. The company was founded in 2016 and has secured significant funding, including a €15.5M Series A round in 2023, and acquired Synsight in July 2024 to enhance their biology platform.